Form DEF 14A - Other definitive proxy statements
SEC Accession No. 0001140361-26-002406
Filing Date
2026-01-26
Accepted
2026-01-26 17:01:25
Documents
21
Period of Report
2026-03-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20058729x1_def14a.htm   iXBRL DEF 14A 821605
6 GRAPHIC logo_outlookthera.jpg GRAPHIC 52140
7 GRAPHIC ny20058729x1_pc01.jpg GRAPHIC 637852
8 GRAPHIC ny20058729x1_pc02.jpg GRAPHIC 478654
9 GRAPHIC ny20058729x1_pvpchart01x1.jpg GRAPHIC 270962
10 GRAPHIC ny20058729x1_pvpchart02.jpg GRAPHIC 258630
  Complete submission text file 0001140361-26-002406.txt   6252794

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA otlk-20260310.xsd EX-101.SCH 3653
3 INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE otlk-20260310_def.xml EX-101.DEF 3142
4 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE otlk-20260310_lab.xml EX-101.LAB 2855
5 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE otlk-20260310_pre.xml EX-101.PRE 6992
23 EXTRACTED XBRL INSTANCE DOCUMENT ny20058729x1_def14a_htm.xml XML 395012
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37759 | Film No.: 26561222
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)